Sanofi, Formation Bio, and OpenAI have announced that they are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software, and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within the pharma and life sciences industries.
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models as it continues on its path to becoming the first biopharma company powered by AI at scale.
Latham & Watkins advised Sanofi in the agreement, with a deal team led by New York partner Aaron Gardner, Boston partner Sarah Gagan, and Bay Area partner Ben Potter, with associates Deborah Hinck and Michael Sweeney.
